Why 10X Genomics (TXG) Acquired ReadCoor And CartaNA AB

By Amit Chowdhry ● October 7, 2020
  • 10X Genomics Inc (NASDAQ: TXG) recently announced it entered into a definitive agreement to buy ReadCoor. And this deal comes on the heels of 10X buying CartaNA AB.

10X Genomics Inc (NASDAQ: TXG) recently announced it entered into a definitive agreement to buy ReadCoor (developer of foundational In Situ technologies) for cash and stock consideration of $350 million. And the announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB (developers of In Situ RNA analysis technology) in late August.

These two acquisitions will give 10x Genomics comprehensive and foundational intellectual property, key technology advances, and deep talent and expertise in the emerging In Situ field.  In Situ technologies will give scientists the ability to measure large numbers of molecules directly in tissue by capturing the precise location of those molecules at sub-cellular resolution.

And these approaches are complementary to the company’s existing Chromium Single Cell and Visium Spatial platforms. With In Situ, 10x Genomics is able to significantly extend its product roadmap to establish the foundation for a third technology platform. And in addition to supporting discoveries made by the Chromium and Visium platforms, In Situ will broaden the range of customers and enable new translational and clinical applications.

ReadCoor spun out of George Church’s lab at Harvard University and CartaNA came out of work from Mats Nilsson’s SciLife Lab at Stockholm University.  And in connection with the acquisitions, George Church and Mats Nilsson will become scientific advisors to 10x Genomics.

Through these transactions, 10x Genomics will acquire over 110 patents and applications that cover multiple foundational In Situ analysis approaches. And these add to its already comprehensive patent portfolio of over 825 issued patents and applications. 10x is going to fund both transactions with a combination of cash from its balance sheet as well as stock. The company expects to provide further details on the market opportunity and product strategy at a later date.

10x expects the Readcoor acquisition to be completed later this month subject to ReadCoor shareholder approval and customary closing conditions. And the CartaNA acquisition has been fully completed.

KEY QUOTES:

“Our goal has always been to anticipate the frontiers of biology and build products that accelerate science in exponential ways. We believe that In Situ approaches will be essential for how biological research and clinical assays will be conducted in the future. After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team. Both companies have made significant technical advances, which will serve as a powerful foundation for future product development at 10x. We look forward to joining forces to help our customers make amazing new discoveries to advance human health.”

— Serge Saxonov, co-founder and CEO of 10x Genomics

“We conceived of In Situ approaches early on as the best way to perform genomic analysis and develop powerful clinical applications. Since then we have been innovating and building out an extensive range of capabilities to bring those ideas to reality and transform the world of biomedicine. We have followed and been impressed with 10x Genomics for years and look forward to combining forces as we execute on a shared vision.”

— Richard Terry, founder and CEO of Readcoor

“Our team has been focused on developing In Situ technologies for a number of years, starting with work at Stockholm University and Karolinska Institute. We are thrilled to join 10x and become a part of their Swedish research center in Stockholm as we continue to build and deliver products for scientists around the globe.”

— Malte Kuhnemund, co-founder and EVP of R&D at CartaNA